Cargando…

Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial

OBJECTIVE: To evaluate the efficacy and safety of metformin in the treatment of amisulpride-induced hyperprolactinemia. METHODS: A total of 86 schizophrenic patients who developed hyperprolactinemia after taking amisulpride were screened and randomly assigned to the metformin group (42 patients) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Cuifang, Li, Ruofan, Ju, Mingliang, Xiao, Xudong, Yuan, Ti-Fei, Jin, Zhixing, Zhao, Jing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205636/
https://www.ncbi.nlm.nih.gov/pubmed/35721320
http://dx.doi.org/10.3389/fnmol.2022.892477
_version_ 1784729170930040832
author Zhu, Cuifang
Li, Ruofan
Ju, Mingliang
Xiao, Xudong
Yuan, Ti-Fei
Jin, Zhixing
Zhao, Jing
author_facet Zhu, Cuifang
Li, Ruofan
Ju, Mingliang
Xiao, Xudong
Yuan, Ti-Fei
Jin, Zhixing
Zhao, Jing
author_sort Zhu, Cuifang
collection PubMed
description OBJECTIVE: To evaluate the efficacy and safety of metformin in the treatment of amisulpride-induced hyperprolactinemia. METHODS: A total of 86 schizophrenic patients who developed hyperprolactinemia after taking amisulpride were screened and randomly assigned to the metformin group (42 patients) and placebo group (44 patients) and followed up for eight weeks. The patients’ serum prolactin levels, blood glucose and lipids were measured at the baseline and the end of the intervention. The treatment emergent symptom scale (TESS) was also assessed. RESULTS: After eight weeks of intervention, serum prolactin levels in the metformin group decreased from (1737.360 ± 626.918) mIU/L at baseline to (1618.625 ± 640.865) mIU/L, whereas serum prolactin levels in the placebo group increased from (2676.470 ± 1269.234) mIU/L at baseline to (2860.933 ± 1317.376) mIU/L. There was a significant difference in prolactin changes (F(covariance) = 9.982, P = 0.002) between the two groups. There was no significant difference in the incidence of adverse drug reactions (P > 0.05) between the two groups. CONCLUSION: Metformin is able to improve amisulpride-induced hyperprolactinemia with its safety.
format Online
Article
Text
id pubmed-9205636
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-92056362022-06-18 Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial Zhu, Cuifang Li, Ruofan Ju, Mingliang Xiao, Xudong Yuan, Ti-Fei Jin, Zhixing Zhao, Jing Front Mol Neurosci Neuroscience OBJECTIVE: To evaluate the efficacy and safety of metformin in the treatment of amisulpride-induced hyperprolactinemia. METHODS: A total of 86 schizophrenic patients who developed hyperprolactinemia after taking amisulpride were screened and randomly assigned to the metformin group (42 patients) and placebo group (44 patients) and followed up for eight weeks. The patients’ serum prolactin levels, blood glucose and lipids were measured at the baseline and the end of the intervention. The treatment emergent symptom scale (TESS) was also assessed. RESULTS: After eight weeks of intervention, serum prolactin levels in the metformin group decreased from (1737.360 ± 626.918) mIU/L at baseline to (1618.625 ± 640.865) mIU/L, whereas serum prolactin levels in the placebo group increased from (2676.470 ± 1269.234) mIU/L at baseline to (2860.933 ± 1317.376) mIU/L. There was a significant difference in prolactin changes (F(covariance) = 9.982, P = 0.002) between the two groups. There was no significant difference in the incidence of adverse drug reactions (P > 0.05) between the two groups. CONCLUSION: Metformin is able to improve amisulpride-induced hyperprolactinemia with its safety. Frontiers Media S.A. 2022-05-26 /pmc/articles/PMC9205636/ /pubmed/35721320 http://dx.doi.org/10.3389/fnmol.2022.892477 Text en Copyright © 2022 Zhu, Li, Ju, Xiao, Yuan, Jin and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Zhu, Cuifang
Li, Ruofan
Ju, Mingliang
Xiao, Xudong
Yuan, Ti-Fei
Jin, Zhixing
Zhao, Jing
Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
title Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
title_full Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
title_fullStr Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
title_full_unstemmed Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
title_short Metformin in the Treatment of Amisulpride-Induced Hyperprolactinemia: A Clinical Trial
title_sort metformin in the treatment of amisulpride-induced hyperprolactinemia: a clinical trial
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9205636/
https://www.ncbi.nlm.nih.gov/pubmed/35721320
http://dx.doi.org/10.3389/fnmol.2022.892477
work_keys_str_mv AT zhucuifang metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial
AT liruofan metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial
AT jumingliang metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial
AT xiaoxudong metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial
AT yuantifei metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial
AT jinzhixing metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial
AT zhaojing metformininthetreatmentofamisulprideinducedhyperprolactinemiaaclinicaltrial